Serum IGF1's diagnostic potential for female heart failure with preserved ejection fraction under investigation in new study

Heart failure with preserved ejection fraction (HFpEF) represents a significant and growing global health challenge, particularly in China, where prevalent HF cases surged by 208.4% to an estimated 14.3 million in 2023. Unlike heart failure with reduced ejection fraction (HFrEF), HFpEF is characterized by substantial heterogeneity in prognosis and often presents diagnostic difficulties, especially in women. Current diagnostic approaches can be complex and may not facilitate early detection, leading to delayed intervention. Investigating novel biomarkers like Insulin-like Growth Factor 1 (IGF1) could offer a more precise and earlier diagnostic tool, addressing a critical gap in managing this complex condition.

This prospective cohort study aims to recruit female patients diagnosed with heart failure with preserved ejection fraction (HFpEF). Participants will undergo collection of relevant medical information during outpatient visits or hospitalization. Blood samples, 10-20 mL of venous blood each time, will be collected concurrently with routine clinical blood draws on the enrollment day, and at 3, 6, and 12 months post-enrollment. These samples will be exclusively used to measure serum IGF1 levels. Standard HF follow-up tests, such as echocardiograms, will be conducted as clinically necessary, forming part of routine HF management.